

Corrigendum

Corrigendum to “Recent Progress in Discovery of Small-Molecule CCR5 Chemokine Receptor Ligands as HIV-1 Inhibitors” [*Bioorg. Med. Chem.* 2003, 11, 2663–2676][☆]

Wieslaw Kazmierski,^{a,*} Neil Bifulco,^a Hanbiao Yang,^a Larry Boone,^b Felix DeAnda,^c
Chris Watson^d and Terry Kenakin^d

^aDepartment of Medicinal Chemistry, GlaxoSmithKline Research and Development, Five Moore Drive, Research Triangle Park, NC 27709-3398, USA

^bDepartment of Virology, GlaxoSmithKline Research and Development, Five Moore Drive, Research Triangle Park, NC 27709-3398, USA


^cComputational, Analytical and Structural Sciences, GlaxoSmithKline Research and Development, Five Moore Drive, Research Triangle Park, NC 27709-3398, USA

^dSystems Research, GlaxoSmithKline Research and Development, Five Moore Drive, Research Triangle Park, NC 27709-3398, USA

Regrettably, the structures of compounds **29–31** were depicted incorrectly in Figure 11 of the above article. The corrected figure is shown below.

In addition, related to this change in Figure 11, the final sentence of the paragraph on page 2667 should read:

SAR explorations of related piperidine-based CCR5 antagonists, done in parallel with the piperazine series exemplified by **29–31**, resulted in discovery of oxime **32** (Sch-C, Fig. 11), which currently is in phase I clinical trials.



	29	30	31	32
RANTES CCR5 IC ₅₀ [nM]	440	2.3	7	2.1
K _i M2 IC ₅₀ [nM]	0.8	2,500	250	n/a
AUC ug.hr/mL	n/a	3.9	9.2	6.5

Figure 11. Piperidine-based CCR5 inhibitors from Schering

[☆]PII of original article: S0968-0896(03)00161-5

*Corresponding author. Fax: +1-919-483-6053; e-mail: wmk35860@gsk.com